Gavekal Capital buys $8,360,114 stake in Henry Schein (HSIC)

Henry Schein (HSIC) : Gavekal Capital scooped up 10,804 additional shares in Henry Schein during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 17, 2016. The investment management firm now holds a total of 54,513 shares of Henry Schein which is valued at $8,360,114.Henry Schein makes up approximately 2.85% of Gavekal Capital’s portfolio.

Other Hedge Funds, Including , Capstone Asset Management Co reduced its stake in HSIC by selling 262 shares or 2.43% in the most recent quarter. The Hedge Fund company now holds 10,512 shares of HSIC which is valued at $1,667,519. Henry Schein makes up approx 0.05% of Capstone Asset Management Co’s portfolio.Vontobel Asset Management Inc boosted its stake in HSIC in the latest quarter, The investment management firm added 35,600 additional shares and now holds a total of 117,093 shares of Henry Schein which is valued at $19,090,843. Henry Schein makes up approx 0.15% of Vontobel Asset Management Inc’s portfolio. Contravisory Investment Management added HSIC to its portfolio by purchasing 93 company shares during the most recent quarter which is valued at $15,163. Simplex Trading added HSIC to its portfolio by purchasing 1,003 company shares during the most recent quarter which is valued at $162,255. Henry Schein makes up approx 0.02% of Simplex Trading’s portfolio.

Henry Schein closed down -2.69 points or -1.72% at $153.36 with 17,31,072 shares getting traded on Friday. Post opening the session at $153.51, the shares hit an intraday low of $149.29 and an intraday high of $154.908 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Henry Schein reported $1.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.63. The company had revenue of $2872.60 million for the quarter, compared to analysts expectations of $2845.09 million. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.46 EPS.

Many Wall Street Analysts have commented on Henry Schein. Shares were Downgraded by Robert W. Baird on Oct 14, 2016 to ” Neutral” and Lowered the Price Target to $ 164 from a previous price target of $176 .Henry Schein was Upgraded by Goldman to ” Buy” on Oct 11, 2016. Henry Schein was Initiated by BofA/Merrill to “Buy” on Sep 12, 2016.

Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Henry Schein - Is it time to Sell?

Top Brokerage Firms are advising their investors on Henry Schein. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.